Tenax Therapeutics, Inc.
TENX
$5.80
$0.030.52%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 35.56% | 19.70% | 3.15% | -8.21% | -11.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 136.75% | 108.66% | 58.09% | 7.39% | -25.50% |
| Operating Income | -136.75% | -108.66% | -58.09% | -7.39% | 25.50% |
| Income Before Tax | -128.27% | -107.01% | -57.58% | -3.80% | 30.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -128.27% | -107.01% | -57.58% | -3.80% | 30.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -128.27% | -107.01% | -57.58% | -3.80% | 30.20% |
| EBIT | -136.75% | -108.66% | -58.09% | -7.39% | 25.50% |
| EBITDA | -136.88% | -108.63% | -58.05% | -7.35% | 25.54% |
| EPS Basic | 84.16% | 86.98% | 92.37% | 94.79% | 94.69% |
| Normalized Basic EPS | 84.15% | 86.99% | 92.37% | 94.79% | 94.70% |
| EPS Diluted | 84.16% | 86.98% | 92.37% | 94.79% | 94.69% |
| Normalized Diluted EPS | 84.15% | 86.99% | 92.37% | 94.79% | 94.70% |
| Average Basic Shares Outstanding | 5,924.11% | 3,337.59% | 767.88% | 1,101.32% | 1,243.15% |
| Average Diluted Shares Outstanding | 5,924.11% | 3,337.59% | 767.88% | 1,101.32% | 1,243.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |